Icotrokinra, also known as JNJ-77242113, is an oral interleukin (IL)-23 receptor antagonist that is being evaluated for moderate to severe psoriasis in phase 3 trials. “One caveat,” Strober ...

"The majority of people living with moderate-to-severe plaque psoriasis are eligible for, but are still not receiving, advanced therapies," she added. "Icotrokinra has the potential to offer once ...

Plaque psoriasis is a chronic condition without a current cure ... You should avoid trying to scrape off or scratch the psoriasis plaques because this can cause trauma to the skin and cause ...

Patient and provider preferences trend towards injectables due to their convenience and sustained efficacy, which are crucial in the management of moderate to severe plaque psoriasis cases.

QX004N, an interleukin-23 inhibitor, showed safety and efficacy in the treatment of moderate to severe plaque psoriasis, according to a study. QX004N, an IL-23 inhibitor, showed safety and ...